Clinical trials: Hepatitis, Alcoholic
Alcoholic Hepatitis
A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis
This clinical trial will test two new therapies for the treatment of alcoholic hepatitis. Patients who "respond" to the current standard of care therapy for alcoholic hepatitis(corticosteroid/prednisolone therapy) after 1 week of…
- Trial name
- NCT01903798
- Testing
- Mycophenolate mofetil, Prednisolone, Rilonacept
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Southern California Institute for Research and Education
Obesity, Insulin Resistance
A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity
Many metabolic complications of obesity are a consequence of abnormal responses of the liver, muscle, and fat to insulin actions. Fenretinide may improve the effects of insulin, preventing metabolic complications.
- Trial name
- NCT00546455
- Testing
- Fenretinide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Diego
Hepatitis, Alcoholic
Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis
Hypothesis: Oral administration of hyperimmune bovine colostrum enriched with anti-LPS antibodies will reduce endotoxemia, and improve pathophysiological and clinical parameters related to severe alcoholic hepatitis (SAH).
- Trial name
- TREAT (NCT01968382)
- Testing
- IMM 124-E (Hyperimmune Bovine Colostrum)
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Virginia Commonwealth University
Alcoholic Hepatitis
Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy
The main purpose of the study is to test if taking a study drug called emricasan (also known as IDN-6556 and PF-03491390) will affect overall patient survival after one month of treatment.
- Trial name
- AH (NCT01912404)
- Testing
- IDN-6556
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Severe Acute Decompensated Alcoholic Hepatitis
Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis
The purpose of this randomised, double-blind, placebo-controlled, phase II study is to assess the efficacy and safety of orally administered DS102 in adult patients with acute decompensated alcoholic hepatitis
- Trial name
- NCT03452540
- Testing
- 1000mg DS102 (BID)
- Where
- 8 sites in United States, Georgia
- Volunteers
- 9 people
- Sponsor
- Afimmune
Alcoholic Hepatitis, Sepsis
Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis
The purpose of this research study is to test the safety, tolerability, and effectiveness of Vitamin C (ascorbic acid) intravenous infusion when used to treat alcoholic hepatitis (inflammation of the liver from heavy alcohol use)…
- Trial name
- CITRIS-AH (NCT03829683)
- Testing
- Vitamin C, Dextrose 5% in water
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Virginia Commonwealth University
Alcoholic Liver Disease
Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease
Background/Aims: The investigators explored the therapeutic effects of probiotics in patients with AH. Methods: Between September 2010 and April 2012, the investigators conducted a 7-day, double-controlled, randomized…
- Trial name
- EPALD (NCT01501162)
- Testing
- hepatitis, alcohol, probiotics
- Where
- South Korea
- Volunteers
- 130 people
- Sponsor
- Chuncheon Sacred Heart Hospital
Non-Alcoholic Fatty Liver Disease, Hepatitis B
A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in Canada
(1) Due to missed childhood vaccination programs, the majority of adult patients with NAFLD in Canada do not have immunity to hepatitis B.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Hepatitis B, Vaccine Reaction
- Trial name
- NCT02985450
- Testing
- Engerix-B
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- University of Calgary
Genotype 1 Hepatitis C Virus
Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics
To determine the efficacy and safety of Harvoni in treatment-naïve alcoholic subjects with Genotype 1 HCV infection
- Trial name
- NCT02759861
- Testing
- harvoni
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Nebraska
Hepatitis
Treating Nonalcoholic Steatohepatitis (NASH) With Metformin
Nonalcoholic Steatohepatitis (NASH) is associated with progressive liver disease, fibrosis, and cirrhosis. Although the cause of NASH is unknown, it is often associated with obesity, type 2 diabetes, and insulin resistance.
- Trial name
- NCT00063232
- Testing
- Metformin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Acute Alcoholic Hepatitis
Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis
This study will compare two different treatments of acute alcoholic hepatitis. The current standard of care is treatment with corticosteroids (methylprednisolone).
- Trial name
- NCT01809132
- Testing
- Anakinra, Pentoxifylline, Zinc Sulfate
- Where
- 4 sites in United States
- Volunteers
- 104 people
- Sponsor
- Mack Mitchell
Acute Alcoholic Hepatitis
Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis
This study is being done to find out whether a diet supplemented with a probiotic nutrient can improve alcoholic hepatitis and gut complications compared to routine standard care.
- Trial name
- NTAH-Mod (NCT01922895)
- Testing
- Lactobacillus Rhamnosus GG
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Texas Southwestern Medical Center
Severe Acute Alcoholic Hepatitis
To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure
The purpose of this study is to determine if treatment with the ELAD System is safe and effective in subjects with severe acute alcoholic hepatitis and Lille score failures (Lille score >0.45).
- Trial name
- NCT01829347
- Testing
- ELAD, Standard of Care treatment
- Where
- 39 sites in United States, Germany and 2 more
- Volunteers
- 18 people
- Sponsor
- Vital Therapies, Inc.
Hepatitis C, Chronic, Non-Alcoholic Fatty Liver Disease
Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation
HepQuant tests are new liver tests that are being developed to accurately measure liver function with sensitivity and specificity while being safe and non-invasive.
- Trial name
- Repro (NCT01579162)
- Testing
- Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- HepQuant, LLC
Alcoholic Hepatitis
Alcoholic Hepatitis Network Observational Study
The purpose of this research study is to create a clinical database and bio-repository. To do this, we will obtain blood, urine, saliva, and stool samples (e.g., biological samples) and personal health information from you to use…
- Trial name
- NCT03850899
- Where
- 9 sites in United States
- Volunteers
- 1,133 people, healthy volunteers welcome
- Sponsor
- Indiana University
Chronic Hepatitis, Chronic Hepatitis C
The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients
The investigators will evaluate the efficacy of high dose vitamin C in chronic hepatitis patients whose serum liver enzymes are elevated more than upper limit.
- Conditions
- Chronic Hepatitis, Chronic Hepatitis C, Chronic Alcoholic Hepatitis
- Trial name
- NCT01413360
- Testing
- High dose vitamin C
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Seoul National University Hospital
Acute Alcoholic Hepatitis
Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
The primary objective of the study is to evaluate safety and efficacy of ELAD® with respect to overall survival (OS) of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) up to at least Study Day…
- Trial name
- NCT01471028
- Testing
- ELAD treatment, Standard of care (Control)
- Where
- 45 sites in United States, Australia and 2 more
- Volunteers
- 203 people
- Sponsor
- Vital Therapies, Inc.
Liver Diseases, Hypertension, Portal
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
This study is open to adults with liver cirrhosis caused by hepatitis B, hepatitis C or nonalcoholic steatohepatitis (NASH). People can join this study if they have high blood pressure in the portal vein (main vessel going to the…
- Trial name
- NCT05282121
- Testing
- Avenciguat, Empagliflozin
- Where
- 31 sites in United States, Argentina and 14 more
- Volunteers
- 90 people
- Sponsor
- Boehringer Ingelheim
Hepatitis
Treating Nonalcoholic Steatohepatitis With Pioglitazone
Nonalcoholic steatohepatitis (NASH) is a common liver disease that resembles alcoholic hepatitis but occurs in persons who drink little or no alcohol.
- Trial name
- NCT00062764
- Testing
- Actos (Pioglitazone)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Acute Alcoholic Hepatitis
Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD
The primary objective of the study is to evaluate safety and efficacy of ELAD with respect to overall survival of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) through at least Study Day 91.
- Trial name
- NCT02612428
- Testing
- ELAD System, Standard of Care (Control)
- Where
- 44 sites in United States, Austria and 4 more
- Volunteers
- 151 people
- Sponsor
- Vital Therapies, Inc.